EU/3/03/171

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2019 at the end of the 10-year period of market exclusivity.

On 17 October 2003, orphan designation (EU/3/03/171) was granted by the European Commission to PharmaMar S.A., Spain, for trabectedin for the treatment of ovarian cancer.

Ecteinascidin 743 in treatment of ovarian cancer has been authorised in the EU as Yondelis since 28 October 2009.

Key facts

Active substance
trabectedin
Medicine name
Yondelis
Disease / condition
Treatment of ovarian cancer
Date of first decision
17/10/2003
Outcome
Expired
EU designation number
EU/3/03/171

Sponsor's contact details

PharmaMar S.A.
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Madrid
Spain
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
E-mail: pharmamar@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating